Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis

CirAE development was associated with more self-reported positive cancer outcomes, reinforcing the presence of DS as a promising indicator of treatment efficacy [2]. [...]patient counseling by dermatologists regarding the prognostic value of cirAEs may improve patient satisfaction. Sentiment analysis tools may also carry biases; for example, our study’s chosen model was trained on social media data, not health care data [7]. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.